Abbott (ABT +3.4%) moves up after initial results from its "Aviator" Phase 2b study of its...

Abbott (ABT +3.4%) moves up after initial results from its "Aviator" Phase 2b study of its interferon-free, investigational regimen for the treatment of hepatitis C indicated that 99% of the "treatment naive" HCV patients - those who had never been previously treated for the virus - showed a sustained virological response. Additionally, 93% of patients in the study who had previously been unsuccessfully treated for HCV also showed sustained virological response.

From other sites
Comments (2)
  • JimHarris
    , contributor
    Comments (8) | Send Message
    As a retired Abt employee of 28 years, my life and financial fortunes are closely tied to Abbott stock since it is a large portion of my IRA. These stats sound so convincing, certainly enough to give the stock a good boost before the upcoming split-up of the company. Abbott is a great place to work as well as a solid, decent dividend company for its investors.
    15 Oct 2012, 04:58 PM Reply Like
  • ladykofla
    , contributor
    Comments (2) | Send Message
    I am a retired ABT employee of 24 years. Abbott was a great place to work and it's an amazing place to be retired from. It's wonderful to always be apart of the Abbott family as an Abbotteer! I didn't sell my stock like alot of people, I held on to it- and I have never been happier, since I retired it's constantly been good news. If I had was a young or experienced investor I would definitely buy when Abbott splits and hold on- you won't be disappointed!
    16 Oct 2012, 02:52 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs